Country: Malaysia
Language: English
Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Lincomycin Hydrochloride (monohydrate); Spectinomycin Sulfate (tetrahydrate)
Life Biopharma Sdn. Bhd.
Lincomycin Hydrochloride (monohydrate); Spectinomycin Sulfate (tetrahydrate)
150 gm; 300 gm; 600 gm; 900 gm
Life Biopharma Sdn. Bhd.
1 FOR ANIMAL USE ONLY Brand or Product Name : LIFE LINCO-SPEC 667MG SOLUBLE POWDER Name and Strength of Active Substance(s) Each gram of LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains Lincomycin 222 mg (equivalent to Lincomycin Hydrochloride 251.74 mg) and Spectinomycin 445 mg (equivalent to Spectinomycin Sulfate Tetrahydrate 672.81 mg). Product Description LIFE LINCO-SPEC 667MG SOLUBLE POWDER is a white or off-white powder for use in drinking water. Target Species Chickens and pigs. Pharmacology Properties LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains the antibiotics lincomycin and spectinomycin, having a complementary spectrum of activity. Lincomycin Lincomycin is a lincosamide antibiotic derived from Streptomyces lincolnensis which inhibits protein synthesis. Lincomycin binds to the 50S sub-unit of the bacterial ribosome close to the peptidyl transfer centre and interferes with the peptide chain elongation process by inhibiting the formation of the 50S sub-unit and by stimulating ribosomal peptidyl-tRNA dissociation. Lincomycin is active against gram- positive bacteria, some anaerobic gram-negative bacteria (such as Brachyspira hyodysenteriae) and mycoplasmas. It has little or no action against gram-negative bacteria such as Escherichia coli. While the lincosamides are generally considered to be bacteriostatic agents, the activity is depending on the sensitivity of the organism and concentration of the antibiotic. Lincomycin may be either bactericidal or bacteriostatic. Resistance to lincomycin is frequently conferred by plasmid-borne factors (erm genes) coding for methylases modifying the ribosomal binding site and frequently leading to cross- resistance to other antimicrobials of the MLSb group. However, the most prevalent mechanism in B. hyodysenteriae and mycoplasmas is the alteration of the binding site through mutational events (chromosomal resistance). Lincomycin resistance mediated by efflux pumps, or by inactivating enzymes, has also been described. There is often complete cross-resistance between linc Read the complete document
1 FOR ANIMAL USE ONLY Brand or Product Name : LIFE LINCO-SPEC 667MG SOLUBLE POWDER Name and Strength of Active Substance(s) Each gram of LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains Lincomycin 222 mg (equivalent to Lincomycin Hydrochloride 251.74 mg) and Spectinomycin 445 mg (equivalent to Spectinomycin Sulfate Tetrahydrate 672.81 mg). Product Description LIFE LINCO-SPEC 667MG SOLUBLE POWDER is a white or off-white powder for use in drinking water. Target Species Chickens and pigs. Pharmacology Properties LIFE LINCO-SPEC 667MG SOLUBLE POWDER contains the antibiotics lincomycin and spectinomycin, having a complementary spectrum of activity. Lincomycin Lincomycin is a lincosamide antibiotic derived from Streptomyces lincolnensis which inhibits protein synthesis. Lincomycin binds to the 50S sub-unit of the bacterial ribosome close to the peptidyl transfer centre and interferes with the peptide chain elongation process by inhibiting the formation of the 50S sub-unit and by stimulating ribosomal peptidyl-tRNA dissociation. Lincomycin is active against gram- positive bacteria, some anaerobic gram-negative bacteria (such as Brachyspira hyodysenteriae) and mycoplasmas. It has little or no action against gram-negative bacteria such as Escherichia coli. While the lincosamides are generally considered to be bacteriostatic agents, the activity is depending on the sensitivity of the organism and concentration of the antibiotic. Lincomycin may be either bactericidal or bacteriostatic. Resistance to lincomycin is frequently conferred by plasmid-borne factors (erm genes) coding for methylases modifying the ribosomal binding site and frequently leading to cross- resistance to other antimicrobials of the MLSb group. However, the most prevalent mechanism in B. hyodysenteriae and mycoplasmas is the alteration of the binding site through mutational events (chromosomal resistance). Lincomycin resistance mediated by efflux pumps, or by inactivating enzymes, has also been described. There is often complete cross-resistance between linc Read the complete document